Hyperbranched Polymer-Based Vaccines for Cancer Immunotherapy

Recently, several immunotherapeutic strategies have been extensively studied and entered clinical investigation, suggesting their potential to lead a new generation of cancer therapy. Particularly, a cancer vaccine that combines tumor-associated antigens and immune adjuvants with a nanocarrier holds...

Full description

Saved in:
Bibliographic Details
Published in:Macromolecular bioscience 2023-11, Vol.23 (11), p.e2300188-e2300188
Main Authors: Wang, Zhiqiang, Guo, Yunqi, Shen, Mingwu, Wang, Yong, Shi, Xiangyang
Format: Article
Language:English
Subjects:
Adjuvants
Antigen (tumor-associated)
Antigens
Antitumor activity
Cancer
Cancer immunotherapy
Cancer therapies
Cancer vaccines
Dendrimers
Immune response
Immunotherapy
Polyethyleneimine
Polymers
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, several immunotherapeutic strategies have been extensively studied and entered clinical investigation, suggesting their potential to lead a new generation of cancer therapy. Particularly, a cancer vaccine that combines tumor-associated antigens and immune adjuvants with a nanocarrier holds huge promise for inducing specific antitumor immune responses. Hyperbranched polymers, such as dendrimers and branched polyethylenimine (PEI) possessing abundant positively charged amine groups and inherent proton sponge effect are ideal carriers of antigens. Much effort has been devoted to design dendrimer/branched PEI-based cancer vaccines. Here, we review the recent advances in the design of dendrimer/branched PEI-based cancer vaccines for immunotherapy. The future perspectives with regard to the development of dendrimer/branched PEI-based cancer vaccines are also briefly discussed. This article is protected by copyright. All rights reserved.
ISSN:1616-5187
1616-5195
DOI:10.1002/mabi.202300188